Medicamen Organics (NSE:MEDIORG) Short-Term Debt: ₹132.48 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MEDIORG Medicamen Organics Ltd NSE:MEDIORG
22 GF Score
Price ₹25.65
! 11 Warning Signs
View Full Analysis

What is Medicamen Organics Short-Term Debt?

Medicamen Organics NSE:MEDIORG 22 Short-Term Debt is ₹132.48 Mil as of Mar. 2026. GuruFocus rates NSE:MEDIORG with a GF Score™ of 22/100. The stock has 11 warning signs investors should review.

Medicamen Organics's Short-Term Debt for the quarter that ended in Mar. 2026 was ₹132.48 Mil.

Medicamen Organics's quarterly Short-Term Debt declined from Mar. 2024 (₹124.95 Mil) to Mar. 2025 (₹121.96 Mil) but then increased from Mar. 2025 (₹121.96 Mil) to Mar. 2026 (₹132.48 Mil).

Medicamen Organics's annual Short-Term Debt declined from Mar. 2024 (₹124.95 Mil) to Mar. 2025 (₹121.96 Mil) but then increased from Mar. 2025 (₹121.96 Mil) to Mar. 2026 (₹132.48 Mil).

Medicamen Organics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Medicamen Organics Short-Term Debt Related Terms

Medicamen Organics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Medicamen Organics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicamen Organics Short-Term Debt Chart

Medicamen Organics Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Short-Term Debt
Get a 7-Day Free Trial 96.05 114.69 124.95 121.96 132.48

Medicamen Organics Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24 Mar25 Mar26
Short-Term Debt Get a 7-Day Free Trial 114.69 104.16 124.95 121.96 132.48
NSE:MEDIORG
22GF Score
Medicamen Organics Ltd NSE:MEDIORG
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ₹132.48 Mil mean?
Medicamen Organics (NSE:MEDIORG) has a Short-Term Debt of ₹132.48 Mil as of Mar. 2026.
Is Medicamen Organics' Short-Term Debt too high?
Medicamen Organics' current Short-Term Debt is ₹132.48 Mil. Overall, Medicamen Organics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Medicamen Organics' Short-Term Debt compare to ZTS?
Medicamen Organics' Short-Term Debt of ₹132.48 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Medicamen Organics's current Short-Term Debt is ₹132.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicamen Organics stock overvalued right now?
Medicamen Organics (NSE:MEDIORG) has a current Short-Term Debt of ₹132.48 Mil. The current Short-Term Debt is ₹132.48 Mil. Medicamen Organics' overall GF Score™ is 22/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Medicamen Organics (NSE:MEDIORG), the current Short-Term Debt is ₹132.48 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medicamen Organics Business Description

Address Ashok Vihar Phase II, 10, Community Center No. 2, New Delhi, IND, 110052
Medicamen Organics Ltd develops, manufactures, and distributes a wide range of pharmaceutical dosage forms, including Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders. The company operates two WHO Good Manufacturing Practice certified facilities in India, producing products for both domestic and international clients. It provides contract manufacturing and loan license services to various pharmaceutical companies and exports to several countries across Africa, CIS, and South Asia. The principal source of revenue is through the manufacturing, export, and contract services focused on generic and branded pharmaceutical formulations.
22GF Score

Get the complete analysis for NSE:MEDIORG

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹25.65
Price